Story perspectives

Q1 2025: Biosimilars Drive Surge in Pharma Profits

6/11/2025

24 5

Summary

Story summary

Sandoz, STADA, and Samsung Bioepis experienced significant financial growth in Q1 2025, fueled by biosimilars in immunology and oncology.
Sandoz reported $2.48 billion in net sales, with biosimilars accounting for $671 million.
STADA's revenue increased by 4%, driven by a 22% surge in its Specialty segment.
Samsung Bioepis achieved a remarkable 236% rise in operating profit, totaling KRW400.6 billion ($280.3 million).
The companies expect ongoing growth through new product launches and portfolio expansion.

1 of 1

Story summary

Sandoz, STADA, and Samsung Bioepis experienced significant financial growth in Q1 2025, fueled by biosimilars in immunology and oncology.
Sandoz reported $2.48 billion in net sales, with biosimilars accounting for $671 million.
STADA's revenue increased by 4%, driven by a 22% surge in its Specialty segment.
Samsung Bioepis achieved a remarkable 236% rise in operating profit, totaling KRW400.6 billion ($280.3 million).
The companies expect ongoing growth through new product launches and portfolio expansion.